3,677,824 Shares in CVS Health Corporation $CVS Purchased by Jupiter Topco LLC

Key Points

• Jupiter Topco LLC purchased 3.68 million CVS Health shares worth approximately $380.5 million, representing about 0.29% of the company. Institutional investors and hedge funds collectively own 80.66% of CVS.
• CVS reported quarterly EPS of $2.58, beating estimates of $1.87, while revenue reached $106.1 billion and rose 7.3% year over year. The company issued fiscal 2026 EPS guidance of $7.90–$8.10.
• CVS pays a quarterly dividend of $0.665 per share, equivalent to a 2.9% annual yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $107.17.

Jupiter Topco LLC purchased a new stake in CVS Health Corporation (NYSE:CVS - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 3,677,824 shares of the pharmacy operator's stock, valued at approximately $380,460,000. Jupiter Topco LLC owned about 0.29% of CVS Health as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of CVS. BlackRock Inc. bought a new stake in CVS Health in the 2nd quarter valued at $12,747,462,000. Norges Bank bought a new position in CVS Health during the 4th quarter worth $1,666,265,000. Wellington Management Group LLP lifted its holdings in shares of CVS Health by 193.2% during the fourth quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator's stock worth $1,473,270,000 after buying an additional 12,233,675 shares in the last quarter. Pzena Investment Management LLC bought a new stake in shares of CVS Health in the second quarter valued at about $1,217,558,000. Finally, Legal & General Group Plc acquired a new position in shares of CVS Health in the second quarter valued at about $948,947,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Price Performance

Shares of NYSE:CVS opened at $92.95 on Wednesday. The firm has a 50 day moving average of $101.73 and a 200-day moving average of $89.20. CVS Health Corporation has a 12 month low of $69.51 and a 12 month high of $110.68. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $118.88 billion, a PE ratio of 24.59, a PEG ratio of 0.86 and a beta of 0.61.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping analysts' consensus estimates of $1.87 by $0.71. The company had revenue of $106.10 billion during the quarter, compared to analysts' expectations of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.CVS Health's revenue was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, equities research analysts predict that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date was Thursday, July 23rd. CVS Health's payout ratio is 70.37%.

Analyst Ratings Changes

Several analysts have weighed in on CVS shares. Robert W. Baird set a $107.00 price objective on shares of CVS Health in a research note on Thursday, August 6th. Deutsche Bank Aktiengesellschaft increased their target price on shares of CVS Health from $88.00 to $92.00 and gave the stock a "buy" rating in a research report on Thursday, May 7th. Piper Sandler reiterated an "overweight" rating and issued a $113.00 price target on shares of CVS Health in a research report on Monday, June 1st. Cantor Fitzgerald boosted their price target on CVS Health from $100.00 to $110.00 and gave the company an "overweight" rating in a research note on Tuesday, July 7th. Finally, Argus lifted their price objective on CVS Health from $104.00 to $114.00 and gave the company a "buy" rating in a report on Wednesday, August 19th. Twenty-two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, CVS Health currently has a consensus rating of "Moderate Buy" and an average price target of $107.17.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source